The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill No. 32 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists. We strongly support the Biologics Competition and Innovation Act (BPCIA) definition of “interchangeable biologic product” which allows a pharmacist to substitute an interchangeable biologic product without the intervention of the health care provider who prescribed the “reference product”. Senate Bill No. 32 includes an amendment to AS. 08.80.295 which allows the pharmacist to substitute an interchangeable biological product with the consent of the patient, we support that amendment because it is consistent with the BPCIA and Alaska law.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
